ReviewFrontiers in immunology2026
Transfer RNA expression, modification, and derived small RNAs in cancer biology and clinical potential.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transfer RNA (tRNA) is essential for protein synthesis and undergoes diverse chemical modifications that regulate its stability and function. Dysregulation of tRNA expression and modifications, along with the activity of tRNA-derived small RNAs (tsRNAs) and aminoacyl-tRNA synthetases, has been increasingly linked to cancer development, influencing tumor proliferation, metastasis, stress responses, and therapy resistance. Here we systematically review the biological features of tRNA and its modifications, elucidate their mechanistic roles in various cancers, and explore the emerging functions of tsRNAs and tRNA-modifying enzymes. We also assess the diagnostic and therapeutic potential of targeting tRNA pathways in oncology. These insights provide a foundation for advancing precision medicine approaches by exploiting tRNA-related mechanisms to improve cancer diagnosis and treatment outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.